© Cass Redstone
We are making cold tumors hot
OncoResponse utilizes a clinically validated Technology Platform to discover authentic human antibodies to multiple high value targets associated with immunosuppressive myeloid biology. We leverage the power of the Elite Responder’s immune system to discover immunomodulatory antibodies from patients who achieve exceptional responses to CPI therapies.
Our pipeline of antibodies is expected to relieve immunosuppression of the TME and augment immune activity to make “cold” tumors “hot”.